Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash Flows from Operating Activities:
Net loss from continuing operations	$ (10,650,464)	$ (16,205,252)
(Loss) income from discontinued operations, net of tax	(1,152,276)	760,165
Gain on sale of discontinued operations	1,434,479
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of discontinued operations	(1,434,479)
Stock-based compensation	827,043	667,682
Depreciation and amortization of intangible assets	83,486	97,113
Amortization of right of use assets	113,774	27,675
Amortization of debt discount	19,549	35,513
Loss on forward purchase agreement	5,700,451	10,268,130
Change in fair value of derivative liabilities		(826,980)
Shares issued for interest		250,000
Changes in operating assets and liabilities:
Inventory	(108,705)
Prepaid expenses	463,809	(659,927)
Income taxes receivable	(97,279)	(204,559)
Accounts receivable	(4,096)
Other current assets		28,175
Assets available for sale	4,662,980	18,938,353
Accounts payable	(359,143)	(449,873)
Accrued expenses and other liabilities	(1,281,721)	570,221
Lease liability	(117,013)	(257,720)
Accrued interest		(109,379)
Income tax payable		(545,441)
Liabilities available for sales	(2,489,343)	(20,732,104)
Net cash used in operating activities	(4,388,948)	(8,348,208)
Cash flows from investing activities:
Purchases of property and equipment		(30,470)
Cash paid in AxoBio Disposition	(748,796)
Net cash used in investing activities	(748,796)	(30,470)
Cash Flows from Financing Activities:
Proceeds from issuance of Common Stock, net of costs	2,687,225
Proceeds from issuance of loans	495,692	1,859,980
Payment of loans	(714,181)	(551,833)
Deferred offering costs	(86,314)
Gross proceeds from Business Combination		30,951,174
Transaction costs paid in connection with the Business Combination		(951,898)
Cash transferred in connection with Forward Purchase Agreement		(17,535,632)
Proceeds from common stock option exercises		41,073
Payment of convertible notes		(2,649,874)
Net cash provided by financing activities	2,382,422	11,162,990
Net increase in cash	(2,755,322)	2,784,312
Cash - beginning of the period	2,912,461	128,149
Cash - end of the period	157,139	2,912,461
Supplemental cash flow information:
Interest paid	29,466	283,526
Income tax paid		750,000
Non-cash financing activity:
Fair value of shares received in AxoBio Disposition	23,456,179
Common Stock issued in connection with conversion of Notes	848,500
Decrease in right of use asset and lease liabilities related to termination of lease	$ 333,003
Net assets acquired in AxoBio Acquisition		43,135,082
Earnout liability and deferred consideration payable in connection with AxoBio Acquisition		21,482,292
Issuance of Series A preferred stock and common stock in connection with AxoBio Acquisition		21,652,790
Accrued Legacy Series A preferred stock dividends		164,510
Accrued Legacy Series C-1 preferred stock dividends		40,551
Accrued Legacy Series C-2 preferred stock dividends		470,962
Debt discount recorded in connection with loans payable		55,062
Conversion of common stock and preferred stock in connection with the Business Combination		$ 32,092,096